170 related articles for article (PubMed ID: 26432058)
1. Essential Thrombocythemia: The Dermatologic Point of View.
Cozzani E; Iurlo A; Merlo G; Cattaneo D; Burlando M; Pierri I; Gugliotta L; Parodi A
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):739-47. PubMed ID: 26432058
[TBL] [Abstract][Full Text] [Related]
2. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
Iványi JL; Marton É; Plander M; Szendrei T
Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous manifestations in patients with essential thrombocythemia.
Itin PH; Winkelmann RK
J Am Acad Dermatol; 1991 Jan; 24(1):59-63. PubMed ID: 1999531
[TBL] [Abstract][Full Text] [Related]
4. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia.
Verstovsek S; Komatsu N; Gill H; Jin J; Lee SE; Hou HA; Sato T; Qin A; Urbanski R; Shih W; Zagrijtschuk O; Zimmerman C; Mesa RA
Future Oncol; 2022 Sep; 18(27):2999-3009. PubMed ID: 35924546
[TBL] [Abstract][Full Text] [Related]
5. Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.
Samuelson B; Chai-Adisaksopha C; Garcia D
J Thromb Thrombolysis; 2015 Nov; 40(4):474-9. PubMed ID: 25894476
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study.
Gugliotta L; Besses C; Griesshammer M; Harrison C; Kiladjian JJ; Coll R; Smith J; Abhyankar B; Birgegård G
Haematologica; 2014 Apr; 99(4):679-87. PubMed ID: 24334294
[TBL] [Abstract][Full Text] [Related]
7. Long-term management of thrombocytosis in essential thrombocythaemia.
Birgegård G
Ann Hematol; 2009 Jan; 88(1):1-10. PubMed ID: 18629498
[TBL] [Abstract][Full Text] [Related]
8. Anagrelide: what was new in 2004 and 2005?
Petrides PE
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):399-408. PubMed ID: 16810615
[TBL] [Abstract][Full Text] [Related]
9. Essential thrombocythemia (ET): moving from palliation to cure.
Tsimberidou AM; Giles FJ
Hematology; 2002 Dec; 7(6):315-23. PubMed ID: 12475736
[TBL] [Abstract][Full Text] [Related]
10. Update on diagnosis and management of essential thrombocythemia.
Gisslinger H
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):430-6. PubMed ID: 16810619
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of essential thrombocythemia].
Costello R; O'Callaghan T; Sébahoun G
Rev Med Interne; 2005 Dec; 26(12):947-55. PubMed ID: 16122842
[TBL] [Abstract][Full Text] [Related]
12. The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia.
Birgegård G
Curr Hematol Malig Rep; 2016 Oct; 11(5):348-55. PubMed ID: 27497846
[TBL] [Abstract][Full Text] [Related]
13. [What vascular events suggest a myeloproliferative disorder?].
Hachulla E; Rose C; Trillot N; Caulier-Leleu MT; Pasturel-Michon U
J Mal Vasc; 2000 Dec; 25(5):382-387. PubMed ID: 11148402
[TBL] [Abstract][Full Text] [Related]
14. Indications for lowering platelet numbers in essential thrombocythemia.
Barbui T
Semin Hematol; 2003 Jan; 40(1 Suppl 1):22-5. PubMed ID: 12682878
[TBL] [Abstract][Full Text] [Related]
15. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.
Gisslinger H; Gotic M; Holowiecki J; Penka M; Thiele J; Kvasnicka HM; Kralovics R; Petrides PE;
Blood; 2013 Mar; 121(10):1720-8. PubMed ID: 23315161
[TBL] [Abstract][Full Text] [Related]
16. Anagrelide-induced relapse of a hydroxyurea-induced leg ulcer in a patient with primary thrombocythemia.
Ruiz-Argüelles GJ; Ruiz-Delgado GJ; Ruiz-Reyes G; Chernoff SG
Mayo Clin Proc; 1998 Nov; 73(11):1125. PubMed ID: 9818051
[No Abstract] [Full Text] [Related]
17. Cost-effectiveness considerations in the treatment of essential thrombocythemia.
Golub R; Adams J; Dave S; Bennett CL
Semin Oncol; 2002 Jun; 29(3 Suppl 10):28-32. PubMed ID: 12096355
[TBL] [Abstract][Full Text] [Related]
18. A critical review of anagrelide therapy in essential thrombocythemia and related disorders.
Dingli D; Tefferi A
Leuk Lymphoma; 2005 May; 46(5):641-50. PubMed ID: 16019501
[TBL] [Abstract][Full Text] [Related]
19. Anagrelide: new drug. Essential thrombocythaemia: further evaluation needed for this last-resort treatment.
Prescrire Int; 2006 Jun; 15(83):83-6. PubMed ID: 16764090
[TBL] [Abstract][Full Text] [Related]
20. Acute biphenotypic leukemia arising in a patient with essential thrombocythemia.
Wong GC; Lee LH
Am J Hematol; 2006 Aug; 81(8):624-6. PubMed ID: 16823822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
